Page last updated: 2024-10-16

adenine and B-Cell Leukemia

adenine has been researched along with B-Cell Leukemia in 8 studies

Research Excerpts

ExcerptRelevanceReference
" We report here the sequential modification of UNC1062 to address DMPK properties and yield a new potent and highly orally bioavailable Mer inhibitor, 11, capable of inhibiting Mer phosphorylation in vivo, following oral dosing as demonstrated by pharmaco-dynamic (PD) studies examining phospho-Mer in leukemic blasts from mouse bone marrow."1.40UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. ( Cummings, CT; DeRyckere, D; Earp, HS; Frye, SV; Glaros, TG; Graham, DK; Hunter, D; Janzen, WP; Kireev, D; Lee, M; Liu, J; Minson, KA; Newton, DL; Sather, S; Stashko, MA; Wang, X; Zhang, D; Zhang, W, 2014)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (87.50)24.3611
2020's1 (12.50)2.80

Authors

AuthorsStudies
Carda, JP1
Santos, L1
Mariz, JM1
Monteiro, P1
Gonçalves, HM1
Raposo, J1
Gomes da Silva, M1
Göckeritz, E1
Vondey, V1
Guastafierro, A1
Pizevska, M1
Hassenrück, F1
Neumann, L1
Hallek, M2
Krause, G1
Zhang, Z1
Zhang, D2
Liu, Y1
Yang, D1
Ran, F1
Wang, ML2
Zhao, G1
McCarter, SJ1
Vijayvargiya, P1
Sidana, S1
Nault, AM1
Lane, CE1
Lehman, JS1
Wilson, JW1
Parikh, SA1
Nowakowski, GS1
Al-Kali, A1
Wang, M1
Xu, W1
Li, JY1
Zhang, W1
DeRyckere, D1
Hunter, D1
Liu, J1
Stashko, MA1
Minson, KA1
Cummings, CT1
Lee, M1
Glaros, TG1
Newton, DL1
Sather, S1
Kireev, D1
Janzen, WP1
Earp, HS1
Graham, DK1
Frye, SV1
Wang, X1
Wang, Y1
Zhang, LL1
Champlin, RE1
Jerkeman, M1
Dreyling, M1
Thieblemont, C1
Kimby, E1
Staudt, L1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant[NCT03689894]Phase 1/Phase 22 participants (Actual)Interventional2019-04-11Terminated (stopped due to Insufficient accrual)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Assess the Response Rate of cGVHD to Treatment With Ibrutinib Plus Rituximab

Response rate of clinically significant GVHD will be assessed using NIH criteria (from 2014 NIH Consensus Development Project). (NCT03689894)
Timeframe: 6 weeks, 3 months, and 6 months after initiation of treatment

InterventionParticipants (Count of Participants)
Ibrutinib Plus Rituximab0

Reviews

4 reviews available for adenine and B-Cell Leukemia

ArticleYear
Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
    Archiv der Pharmazie, 2018, Volume: 351, Issue:7

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Autoimmune Diseases; B

2018
[Ibrutinib in the treatment of chronic lymphocytic leukemia and other B-cell malignancies].
    Zhongguo shi yan xue ye xue za zhi, 2014, Volume: 22, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Leukemia, B-Cell; Leukemia, Lymphocytic, Chron

2014
Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.
    Clinical pharmacology and therapeutics, 2015, Volume: 97, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Drug Discovery; Humans

2015
Targeting of B-cell receptor signalling in B-cell malignancies.
    Journal of internal medicine, 2017, Volume: 282, Issue:5

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Humans

2017

Other Studies

4 other studies available for adenine and B-Cell Leukemia

ArticleYear
Management of ibrutinib treatment in patients with B-cell malignancies: clinical practice in Portugal and multidisciplinary recommendations.
    Hematology (Amsterdam, Netherlands), 2021, Volume: 26, Issue:1

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Disease Management; Humans; Leukemia, B-Cell; Patient

2021
Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the micro-environmental dialogue.
    British journal of haematology, 2017, Volume: 178, Issue:6

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; B-Lymphocytes; Chemokines; Chem

2017
A case of ibrutinib-associated aspergillosis presenting with central nervous system, myocardial, pulmonary, intramuscular, and subcutaneous abscesses.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:2

    Topics: Abscess; Adenine; Antifungal Agents; Aspergillosis; Humans; Leukemia, B-Cell; Lymphoma, B-Cell; Orga

2019
UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.
    Journal of medicinal chemistry, 2014, Aug-28, Volume: 57, Issue:16

    Topics: Adenine; Administration, Oral; Animals; Biological Availability; c-Mer Tyrosine Kinase; Cell Line, T

2014